{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:33:29Z","timestamp":1788402809694,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA076930"],"award-info":[{"award-number":["K12CA076930"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K24CA184039"],"award-info":[{"award-number":["K24CA184039"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clml.2015.02.021","type":"journal-article","created":{"date-parts":[[2015,3,5]],"date-time":"2015-03-05T03:52:16Z","timestamp":1425527536000},"page":"392-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"15","author":[{"given":"Ryan D.","family":"Cassaday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purvi","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Nachankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.021_bib1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.2009.013359","article-title":"Mantle cell lymphoma","volume":"94","author":"Pileri","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.021_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma","volume":"142","author":"Jares","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.021_bib3","first-page":"1591","article-title":"Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas: correlation with cyclin D1 (PRAD1\/CCND1) mRNA levels and proliferative activity","volume":"148","author":"Jares","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2015.02.021_bib4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2015.02.021_bib5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1517\/14728222.11.7.929","article-title":"Novel therapeutic targets in mantle cell lymphoma","volume":"11","author":"Martin","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.clml.2015.02.021_bib6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/1535-7163.MCT-06-0613","article-title":"In\u00a0vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00","volume":"6","author":"Joshi","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2015.02.021_bib7","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/1535-7163.MCT-06-0614","article-title":"P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in\u00a0vivo efficacy in tumor models","volume":"6","author":"Joshi","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2015.02.021_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1476-4598-11-77","article-title":"P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in\u00a0vitro and in\u00a0vivo in mantle cell lymphoma cell lines","volume":"11","author":"Shirsath","year":"2012","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clml.2015.02.021_bib9","unstructured":"Hirte H, Digumarti R, Baetz T, et\u00a0al. A phase I study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms: final report. Paper presented at: 100th AACR Annual Meeting April 18-22, 2009; Denver, CO. Cancer Res, 69, Abstract 3308."},{"key":"10.1016\/j.clml.2015.02.021_bib10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.021_bib11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.021_bib12","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.021_bib13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.021_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.021_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.021_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1479-5876-10-161","article-title":"Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers","volume":"10","author":"Rathos","year":"2012","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clml.2015.02.021_bib17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/1535-7163.MCT-12-0102","article-title":"CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis","volume":"11","author":"Subramaniam","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2015.02.021_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-13-29","article-title":"Potentiation of in\u00a0vitro and in\u00a0vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells","volume":"13","author":"Rathos","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2015.02.021_bib19","unstructured":"Clinicaltrials.gov [Web site]. A phase I\/II study to evaluate safety and efficacy of P276-00 in combination with gemcitabine in patients with cancer of pancreas (SAVIOR). Available at: http:\/\/clinicaltrials.gov\/show\/NCT00898287. Accessed: September 19,\u00a02013."},{"key":"10.1016\/j.clml.2015.02.021_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jnci\/djs002","article-title":"Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy","volume":"104","author":"Roberts","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2015.02.021_bib21","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.021_bib22","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity","volume":"108","author":"Marzec","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.021_bib23","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.021_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders","volume":"28","author":"Lin","year":"2010","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T17:28:58Z","timestamp":1537810138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S2152265015000658"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}